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Aims. To estimate the prevalence of blindness in theRepublic of Ireland and the associated financial and total economic cost between
2010 and 2020.Methods. Estimates for the prevalence of blindness in the Republic of Ireland were based on blindness registration
data from the National Council for the Blind of Ireland. Estimates for the financial and total economic cost of blindness were based
on the sumof direct and indirect healthcare and nonhealthcare costs.Results.We estimate that there were 12,995 blind individuals in
Ireland in 2010 and in 2020 there will be 17,997. We estimate that the financial and total economic costs of blindness in the Republic
of Ireland in 2010 were €276.6 million and €809 million, respectively, and will increase in 2020 to €367 million and €1.1 billion,
respectively. Conclusions. Here, ninety-eight percent of the cost of blindness is borne by the Departments of Social Protection and
Finance and not by the Department of Health as might initially be expected. Cost of illness studies should play a role in public
policy making as they help to quantify the indirect or “hidden” costs of disability and so help to reveal the true cost of illness.
1. Introduction
The World Health Organization predicts that by 2020 there
will be seventy-six million blind people worldwide. The
Vision 2020 Global Initiative aims to eliminate the main
causes of avoidable blindness by the year 2020 by facili-
tating the planning, development, and implementation of
sustainable national eye care programmes. If this initiative is
successfully implemented, it is estimated that the number of
blind individuals globally will fall to 24 million by 2020 [1].
Visual impairmentmay be broadly defined as a limitation
in one or more functions of the eye and/or visual system. It
has a major impact on the daily lives of those affected as well
as considerable economic effects on these individuals, their
families, support agencies, society, and the state.
Currently, the main causes of blindness in Ireland are age
related macular degeneration, glaucoma, cataract, retinitis
pigmentosa, and diabetic retinopathy [2]. The numbers of
those registered as blind in the Republic of Ireland between
2007 and 2008 due to these five main causes are given in
Table 1.
It has already been estimated that the direct healthcare
cost of visual impairment to the Republic of Ireland was
€2.143 billion in 2010 and could rise to €2.673 billion by
2020 [3]. In arriving at this estimate, all degrees of visual
impairment, that is, mild visual impairment in which best
corrected visual acuity <6/12 but >6/18 and moderate visual
impairment in which best corrected visual acuity <6/18 but
>6/60 as well as blindness in which best corrected visual
acuity <6/60, were considered and the costs due to each
“category” of visual impairment were not elaborated.
The aim of this study is to estimate the prevalence of
blindness in the Republic of Ireland and estimate the financial
and total economic cost that relates to blindness alone
between 2010 and 2020. In this study, blindness is defined as
having either a visual acuity of 6/60 or less in the better eye
and/or a visual field restricted to twenty degrees or less.
The financial cost of blindness includes direct and
indirect healthcare costs. The direct costs of blindness are
those incurred within the healthcare system by the govern-
ment and/or other payers as a result of treating blindness.
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Table 1: Numbers of those registered as blind in the Republic of Ireland according to age and category in 2007/2008.
Age range Age related macular degeneration Glaucoma Cataract Retinitis pigmentosa Diabetic retinopathy Total registered
45–54 12 21 26 105 36 766
55–64 38 29 38 116 55 886
65–74 138 66 35 69 82 985
75–84 745 142 41 58 80 1952
85+ 1311 276 63 22 36 2955
Total registered 2244 534 203 370 289 7544
A significant proportion relates to expenditure on healthcare
service utilisation, the provision of equipment, drug costs,
and the cost of procedures. The cost of the increased inci-
dence of depression [4, 5] and the occurrence of injurious
falls [6] in those who are blind have been found to contribute
significantly to the indirect healthcare costs of blindness and
so are also addressed here.
The direct nonhealthcare costs of blindness reflect the
economic impacts of this condition outside of the healthcare
system, on wider society. These include productivity losses
from lost earnings produced by an inability to work due to
blindness or lower employment for the same reason and the
cost of the provision of informal care. Deadweight welfare
losses are losses associated with having to raise additional tax
revenue to publicly fund both healthcare services and welfare
payments to the blind and the taxation revenue that is lost as
a result of blindness form the indirect nonhealthcare costs of
blindness.
The actual financial costs described above and an eco-
nomic valuation of the “burden of disease” together define
the total economic cost of blindness. The burden of disease is
quantified using the economic value of disability adjusted life
years, DALYs, which include healthy years of life lost due to
disability and life lost due to premature death associated with
blindness.
2. Methods
2.1. Prevalence of Blindness. In the Republic of Ireland, the
National Council for the Blind of Ireland (NCBI) maintains a
national register of “blind” people. To be eligible for registra-
tion, an individual must be identified by an ophthalmologist
to have a visual acuity of 6/60 or less from their better eye on
a Snellen chart and/or a binocular visual field restricted to 20
degrees or less. Registration is not mandatory and there is a
history of underregistration. Kelliher et al. in 2006 found this
to be 21.3% [7]. Thus, the total number of blind individuals
registered with NCBI is multiplied by 1.271 (1/1 − 0.213) to
adjust for underregistration.
2.2. Direct and Indirect Healthcare Costs. The direct costs
of visual impairment and blindness in the Republic of
Ireland have previously been calculated by Deloitte Access
Economics (DAE) [3]. It was estimated that in 2010 the
total direct costs (hospital, prescription, general ophthalmic
services, and capital and noncapital expenditure costs) of
treating visual impairment as a whole were €116,754,168.This
was projected to increase to €127.4 million in 2015 and reach
€136.8 million in 2020. The proportion of these costs that
could be attributed specifically to blindness was not analysed.
DAE carried out a similar cost of illness study in Australia
[8] and found that only 1.7% of direct costs resulting from
all degrees of visual impairment were due to blindness. This
paper assumes that the direct costs of the different degrees
of visual impairment in the Republic of Ireland is the same as
that of Australia.Therefore, the direct cost of blindness will be
1.7% of the total direct cost of all degrees of visual impairment
as already outlined by DAE.
Depression has been found to be more prevalent in the
visually impaired population than the non-visually impaired
population [4, 5, 9–13], 32.5% in the former compared to
16.5% in the latter [4]. It is assumed that the rate of depression
in blind individuals is equal to the rate of depression in those
with mild and moderate visual impairment. Thus, the excess
prevalence of depression in the blind population is 16.5%.
$610.10, the cost of treating depression, is taken from an
American study [14] and adjusted using purchasing power
parity and inflation to 2010 euro value.This costmultiplied by
the excess prevalence of depression in the blind that is 16.5%
is the excess cost of depression in the blind population.
The prevalence of injurious falls is higher in those with
visual impairment when compared to those without visual
impairment [6, 15–19].The total cost of injurious falls of those
aged over 65 in the Republic of Ireland in 2008 was estimated
to be €377.27 million [16]. As they are addressed later in this
study, and to avoid the possibility of double counting, the
cost of carers (€15.8 million), the cost of reduced quality of
life (€53.65 million), and the cost of mortality (€135 million)
associated with falls are omitted here. After these costs have
been excluded, the cost of injurious falls is estimated to be
€172.78 million.
According to Scuffham et al., the falls of the visually
impaired account for 21% of the cost of all injurious falls [6].
However, falls caused directly by visual impairment account
for 10% of the cost of falls [6].This 10% of the cost of injurious
falls represents the falls of all those visually impaired. It is
assumed that the cost of falls in blind individuals is equal
to the cost of falls in those with mild and moderate visual
impairment. Therefore, blindness accounts for 5.78%, 6.19%,
and 6.62% (the prevalence of blindness in the Republic of
Ireland/the prevalence of all degrees of visual impairment in
the Republic of Ireland) of the cost of falls attributable to
visual impairment in the Republic of Ireland that is 10% of
the total cost of injurious falls for the years 2010, 2015, and
2020 respectively.
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2.3. Direct and Indirect Nonhealthcare Costs. Blind people are
less likely to be employed compared to people with no visual
impairment. Further, blind people who are employed may
be less productive as a result of their disability. Productivity
losses due to visual impairment will depend on the age of the
person when blindness first occurs. In general, the younger
the blind person the greater the impact of their sight loss on
productivity [20].
Frick and Foster assumed that the proportion of produc-
tivity lost is equal to the DALY weight for blindness which
is 0.600 [1] believing that although the relationship between
the DALY and productivity may not be linear the use of this
figure leads to a conservative estimate of the productivity
losses associated with blindness.
Although Frick and Foster used the age group 15–64 in
their calculations, this is altered to include only those aged
18–64 years as this likely provides a more accurate reflection
of the true productivity losses in the Republic of Ireland. An
equal distribution of blind individuals for the years 15, 16, 17,
18, and 19 is assumed. The sum of those aged 18 and 19 years
who are blind in the Republic of Ireland that is 107 is used
to calculate productivity losses instead of the total number of
blind individuals between the ages of 15 and 19.
Not all of those within the cohort of 18–64 years old that
are available to work choose to participate in the workforce.
This may be due to the individual being unable to seek
work, being unable to gain employment, or choosing not
to work, due to a partner’s ability to support them, for
example, or because the incentive to work is not high enough.
This is known as the “employment-to-population ratio.” The
total number of blind individuals in the age bracket of 18–
64 years is multiplied by this employment-to-population
ratio to estimate the number of blind people that would
participate in the workforce were they not visually impaired.
This employment-to-population ratio is estimated for the
general population. It is assumed that the blind cohort would
have similar employment characteristics to the general public
were they not blind. The employment-to-population ratio
was 60.4% in 2010 according to the Central Statistics Office.
The average annual earnings in 2010 (€35,905) will be used to
calculate the productivity losses associated with blindness for
the year 2010 and also 2015 and 2020.
There is no Republic of Ireland specific data to estimate
the number of informal care hours provided to the blind and
so data on the informal care hours provided by those aged
over 15 years in the Republic of Ireland for all conditions
is considered [3]. This information, given in Table 2, shows
that, for a range of conditions, 58% of informal carers provide
between 1 and 14 hours of informal care per week, 11%
provide 15–28 hours of informal care per week, and so
forth. This report assumes that the informal care provided
to blind people is the same as the informal care provided for
other conditions. The lowest number in each hours per week
category is used. Therefore, it is assumed that 58% of blind
people receive one hour, 11% receive 15 hours, 6% receive 19
hours, and 25% receive 43 hours of informal care per week.
To calculate the economic cost to society of the provi-
sion of informal care, Deloitte Access Economics used the
methodology of van den Berg et al. [21] and used the average
Table 2: The number of informal care hours provided by informal
carers over the age of 15 years in the Republic of Ireland.
Hours of informal
care provided per
week
Reported hours
of informal care
received
Percentage of the blind
population receiving
such hours of informal
care per week
1–14 1 58%
15–28 15 11%
29–42 29 6%
43+ 43 25%
From the Central Statistics Office 2007.
hourly earnings in the Republic of Ireland in 2010 which was
€21.79 as the value of each hour of informal care provided.
Another option is to use the minimum hourly wage for the
Republic of Ireland in 2010 which was €8.65 as the value
of each hour of informal care provided. Given that these
estimates likely over- and underestimate the cost of informal
care, respectively, €15.22, the average of these two values is the
value placed on each hour of informal care provided.
The public funding of healthcare, welfare payments to
the blind, and taxation revenue which is lost as a result
of blindness mean that the government must increase tax
revenue to reach a budget neutral position. Consequently,
tax rates may be higher than they otherwise would have
been. An increase in taxes on goods and services results in a
loss of market efficiency. Consequently, there is an associated
reduction in consumer and producer surplus which is termed
the deadweight welfare loss, or excess burden of tax.
Deadweight welfare loss refers to the cost of lost efficiency
due to
(a) the need to raise additional taxation to provide health
care resources for the management of blindness;
(b) the need to raise additional taxation to provide social
welfare payments to the blind;
(c) lost taxation revenue to the government due to unem-
ployment, lower employment, and lower expenditure
amongst those that are blind.
This study estimated the deadweight welfare loss associated
with blindness using the same methods as those adopted by
DAE [3].
2.4. The Burden of Disease. DALYs are a nonfinancial
approach to measuring the loss of well-being and premature
mortality caused by illness or disease [18]. The DALY value
for a blind individual is 0.6 which estimates that blind
people experience a 60% lower quality of life than a healthy
individual. In their estimate of the cost of disease burden
due to visual impairment in the Republic of Ireland, DAE
estimated the DALYs lost for those with mild and moderate
visual impairment as well as for blind individuals and applied
the monetary value of a statistical life year to convert these
into a financial cost [3]. The number of DALYs lost due
to blindness alone in the Republic of Ireland in 2010 was
estimated to be 5,588 and is estimated to increase to 7,739
years in 2020.
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Table 3: The estimated prevalence of blindness in the Republic of
Ireland 2010–2020.
Age group 2010 2015 2020
Male Female Male Female Male Female
0–4 43 51 48 56 49 57
5–9 80 69 89 76 98 83
10–14 144 122 156 134 172 147
15–19 142 125 150 130 161 142
20–24 163 164 150 148 153 150
25–29 189 189 166 172 147 150
30–34 214 202 247 234 213 209
35–39 240 217 279 248 316 283
40–44 239 248 279 284 320 321
45–49 259 247 288 264 334 300
50–54 273 263 309 298 341 318
55–59 300 305 333 339 376 384
60–64 347 285 381 314 424 349
65–69 339 283 432 362 478 400
70–74 383 388 463 454 597 583
75–79 483 610 563 676 699 802
80–84 628 952 780 1032 954 1170
85–89 577 1223 732 1359 981 1544
90+ 603 1406 964 1883 1,442 2349
Total 5,647 7349 6,809 8,463 8,256 9741
Combined total 12,996 15,272 17,997
Largely due to the paucity of particularly Irish data, there
is an unavoidable degree of uncertainty surrounding the cost
of blindness in the Republic of Ireland and so a sensitivity
analysis is conducted around each point estimatewith a±20%
variation used on most cost components. This is in keeping
with the guidelines for budget impact analysis of health
technologies in Ireland [3]. The exception to this is informal
care costs, where the €8.65 (minimum hourly wage in 2010;
lower estimate) and €21.79 (average hourly wage in 2010;
higher estimate) costs per hour of informal care provided
were used as we believe that these values better predict the
monetary value of informal care provided. Internationally,
deadweight welfare losses are estimated to be in the range
of 9, 16, and 50 cents (9%, 16%, and 50%, resp.) for every
additional tax euro raised by the government. The effect of
reducing the deadweight welfare loss parameter estimate to
the lower bound of 9% was also examined as described by
Roberts et al. in 2010 [22].
3. Results
As Table 3 shows, the prevalence of blindness in the Republic
of Ireland in 2010 is estimated at 12,955. This figure is
anticipated to increase to 17,997 by 2020. The direct, indirect,
and burden of disease costs are detailed in Table 4. The
value within the brackets indicates the average cost per blind
individual per year. Sensitivity analysis is presented inTable 5.
All costs are based on 2010 costs.
4. Discussion
In the Republic of Ireland, the prevalence of blindness in
2003 was estimated to be 227 cases per 100,000 adults
based on NCBI register data. However, it is noted that data
obtained specifically from national registers of blindness can
significantly underestimate the true national prevalence of
both visual impairment and blindness [7, 23, 24]. Previous
UK studies have found 45–60% nonregistration rates among
those eligible for partial sight or blindness registration [23,
24]. In particular, Barry and Murray found 45% of eligible
patients were not appropriately registered, 72% for partial
sight registration and 28% for blindness registration [25].
Kelliher et al. examined underregistration in the Republic of
Ireland and found that 21%of patients at an out-patients clinic
were not appropriately registered [7].While this is lower than
estimates from the aforementioned studies, it nonetheless
suggests that underregistration is a concern when using
register data alone to estimate prevalence of blindness in
the Republic of Ireland. If the underregistration of blindness
in the Republic of Ireland was similar to the 28% found in
the United Kingdom [25] the prevalence of blindness in the
former would be expected to increase from 25,563 in 2010 to
32,721 in 2020.
The total financial cost of blindness is estimated to be
€276.6million in 2010 and is projected to rise to €370million
in 2020. Indirect costs are the largest contributors to the
financial cost of blindness.
Direct costs account for just 1.96% of the financial cost of
blindness.The authors acknowledge that the assumption that
blindness accounts for just 1.7% of the total direct healthcare
costs associated with visual impairment might be considered
unusual. Blindness is however often irreversible and a dete-
rioration in vision to that which provides for registration
as blind may imply that available treatment options have
been exhausted. Conversely, those with mild or moderate
impairments of their vision may still have treatment options
open to them to restore vision or to prevent further vision
loss.
It has already been suggested that the direct costs of
blindness reduce after only one year of blindness [26].
Combined, indirect costs account for 98.04% of the
financial cost of blindness. It is interesting to find that in
2010 one in every three blind individuals was of working
age (18 to 64 years). This is the primary reason that the
cost of lost productivity in 2010 was estimated at almost €58
million. Shamanna et al. estimate that only 20% of blind
people were productive and only 25% were as productive as
an “average” worker [27]. Thus, our estimations of indirect
costs are conservative relative to other similar studies.
With an average cost of €11,650 per blind individual, the
highest indirect cost is that of informal care. This highlights
the crucial role that informal carers play in the lives of blind
individuals and the burden of care such carers alleviate from
the state.
Regarding the measurement of deadweight welfare loss,
we are mindful of the uncertainties inherent in these cal-
culations and acknowledge that assumptions made in such
calculations may not pertain to the Republic of Ireland in
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Table 4: The average and total direct and indirect healthcare and nonhealthcare costs and burden of disease costs 2010–2020.
2010 2015 2020
(A) Healthcare costs
Direct healthcare costs due to blindness €1,984,821(€153)
€2,166,130
(€142)
€2,325,585
(€129)
Cost of depression due to blindness €1,335,821(€103)
€1,569,680
(€103)
€1,850,002
(€103)
Cost of injurious falls due to blindness €998,668(€77)
€1,069,508
(€70)
€1,143,804
(€64)
Total €4,319,310(€332)
€4,805,318
(€315)
€5,319,391
(€296)
(B) Nonhealthcare costs
Lost productivity €57,916,287(€4,457)
€63,043,004
(€4,129)
€67,779,362
(€3,766)
Informal care €151,391,392(€11,650)
€177,896,717
(€11,650)
€209,665,119
(€11,650)
Deadweight loss €63,016,816(€4,849)
€74,059,349
(€4,850)
€84,192,487
(€4,678)
Total €272,324,495(€20,956)
€314,999,070
(€20,643)
€361,636,968
(€20,094)
Total financial cost of blindness, (A) + (B) €276,643,805
(€21,289)
€319,804,388
(€20,943)
€366,956,359
(€20,390)
(C) Economic value of lost well-being €532,552,692(€40,981)
€626,019,576
(€40,997)
€738,350,466
(€41,026)
Total economic cost of blindness, (A) + (B) + (C) €809,196,497
(€62,270)
€945,823,964
(€61,940)
€1,105,306,825
(€61,416)
2015. Although the financial cost of blindness is projected
to increase by 32.6% between 2010 and 2020 the average
financial cost of blindness per patient is estimated to reduce
from €21,288 in 2010 to €20,390 in 2020. This is due to two
factors:
(1) The percentage of blind people increases at a rate
greater than the total direct medical cost estimated.
Therefore, although the direct medical cost due to
blindness increases, this cost is shared among more
blind individuals.
(2) Although the total cost of productivity losses
increases, it is estimated that the proportion increase
in those who are blind and aged over 65 will be higher
than those of working age (18–64), meaning that the
average cost of productivity loss per capita will be
lower in 2020.
The cost of providing social welfare and the blind pension
have not been included in the above costs as these are transfer
payments, not costs. Transfer payments occur where there
is a payment from one economic entity to another with no
good or service produced in return for payment. In economic
terms this is not categorised as a real cost that is where a good
or service is produced in return for payment.
DAE estimated the average financial cost of vision loss
to be €1,717 per annum in 2010 [3]. This is considerably
lower than the average financial cost of blindness (€21,288) in
this study. This paper estimates that blindness accounted for
71.66% of the total financial cost of visual impairment in the
Republic of Ireland in 2010. This is a significant proportion
considering that blind individuals represent just 5.78% of the
visually impaired population.
The economic cost of blindness is the sum of the financial
costs of blindness and the costs associated with the burden
of blindness. The total economic cost of blindness in 2010
is estimated to be €809.2 million. This is anticipated to rise
to over €1.1 billion annually. The highest percentage cost of
the economic cost is the disease burden of blindness which
accounted for 66.8% of the total cost in 2010. Figure 1(a)
shows the rising annual financial and economic costs of
blindness predicted in the Republic of Ireland. Figure 1(b)
identifies the average financial and economic costs of blind-
ness per blind individual between 2010 and 2020.
The average cost of sight loss in the Republic of Ireland is
estimated to be €9,533 compared to €62,270 for the average
cost of blindness in this study. This suggests that the cost of
visual impairment rises when its severity increases. This is
supported by a recent study in the Netherlands where it was
estimated that the annual cost of vision loss in an individual
was €2,752 when the individual was mildly visually impaired
but €23,331 when the individual was blind [28]. Further, these
findings support the notion that interventions to prevent
those with mild and moderate visual impairment from
becoming blindwould reduce the cost of vision loss to society
in the Republic of Ireland. In anAustralian study, it was found
that for every dollar spent on eye care and the reduction
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Table 5: Sensitivity analysis 2010–2020. The table illustrates the upper (+20%) and lower (−20%) limits around each point estimate. For
informal care costs, €21.79 (average hourly wage in 2010) is used as the higher estimate and €8.65 (minimum hourly wage in 2010) is used
as the lower estimate of the cost per hour of informal care provided. The effect of reducing deadweight welfare losses to 9% gives the lower
estimate for this parameter. This table thus provides a range and a mean or “likely” figure for the costs associated with blindness.
2010 2015 2020
(A) Healthcare costs
Direct healthcare costs due to blindness €1,587,857€2,381,785
€1,732,904
€2,599,356
€1,860,468
€2,790,702
Cost of depression due to blindness €1,068,656€1,602,985
€1,255,744
€1,883,616
€1,480,002
€2,220,002
Cost of injurious falls due to blindness €798,934€1,198,492
€915,943
€1,283,409
€915,043
€1,372,565
Total €3,455,447€5,183,262
€3,904,591
€5,766,381
€4,255,513
€6,383,269
(B) Nonhealthcare costs
Lost productivity €46,333,030€69,499,544
€50,434,403
€75,651,605
€54,223,490
€81,335,234
Informal care €86,040,623€216,742,794
€101,104,245
€254,689,190
€119,159,217
€300,171,020
Deadweight loss €50,413,452€75,620,179
€59,247,479
€88,871,219
€67,353,990
€101,030,984
Total €182,787,105€361,862,517
€210,786,127
€419,212,014
€240,736,697
€482,537,238
Total financial costs of blindness, (A) + (B) €186,242,552€367,045,779
€214,690,718
€424,978,395
€244,992,210
€488,920,507
Average financial cost per blind individual
(higher estimate) €28,245 €27,831 €27,167
Average financial cost per blind individual
(lower estimate) €14,332 €14,060 €13,613
(C) Economic value of total DALYs €426,042,153€639,063,230
€500,815,661
€751,223,491
€590,680,373
€886,020,559
Total economic cost of blindness, (A) + (B) +
(C)
€608,829,258
€1,000,925,747
€711,601,788
€1,170,435,505
€831,417,070
€1,368,557,797
Average economic cost per blind individual
(higher estimate) €77,024 €76,649 €76,044
Average economic cost per blind individual
(lower estimate) €46,851 €46,601 €46,198
of sight loss there could be a 4.8-fold financial return to
communities [29].
5. Conclusion
Our knowledge and understanding of the real number of
blind peoplemust be greatly improved if we are to be effective
in planning and delivering services to the people living
with sight loss in the Republic of Ireland. Blindness has a
significant economic impact on those directly affected by
it, those who care for those directly affected, and society
as a whole. The financial cost of blindness in the Republic
of Ireland is estimated to be €276.6 million in 2010 and is
expected to increase by 32.6% by 2020. The current esti-
mates and projections of economic burden have significant
implications for ophthalmology service requirements and the
organisations providing rehabilitation and support services
in Ireland in the future. It is hoped that they will form
part of a comprehensive planning process for this sector of
the population into the future. The direct healthcare costs
of blind individuals represent just 1.96% of the total cost
of blindness. Unless the indirect effects of disabilities and
the costs thereof, the requirements for informal care and
losses in productivity, are acknowledged and incorporated
into decisionmaking at a government level, resources will not
be allocated appropriately to disabilities like blindness which
may directly incur relatively low costs but exert substantial
impacts on quality of life.
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Figure 1: (a) The projected differential increase in the total financial and economic costs of blindness in the Republic of Ireland 2010–2020.
(b) The projected differential increase in the average financial and economic costs of blindness in the Republic of Ireland 2010–2020. (c) The
financial cost of blindness in the Republic of Ireland. Nonhealthcare costs account for 98.44% of the total financial cost of blindness. (d)
The economic cost of blindness in the Republic of Ireland. The cost of disease burden accounts for 65.81% of the annual economic cost of
blindness.
this paper. The authors David Green, Gilles Ducorroy, and
Adrian Skelly declare that they are employees of Novartis
Ireland Ltd. and own shares in Novartis Pharma AG, Basel,
Switzerland.
References
[1] K. D. Frick and A. Foster, “The magnitude and cost of global
blindness: an increasing problem that can be alleviated,”Ameri-
can Journal of Ophthalmology, vol. 135, no. 4, pp. 471–476, 2003.
[2] A. J. Jackson and C. O’Brien, Eyes on the Future Ireland 2008:
A Study into the Prevalence of Blindness and Visual Impairment,
Vision Impaired Service Providers Alliance, 2008.
[3] Deloitte Access Economics,TheCost of Sight Loss:The Economic
Impact of Vision Impairment and Blindness in the Republic of
Ireland, Deloitte Access Economics, 2011.
[4] B. L. Brody, A. C. Gamst, R. A. Williams et al., “Depression,
visual acuity, comorbidity, and disability associated with age-
related macular degeneration,” Ophthalmology, vol. 108, no. 10,
pp. 1893–1900, 2001.
[5] M. L. Bruce, T. E. Seeman, S. S. Merrill, and D. G. Blazer, “The
impact of depressive symptomatology on physical disability:
MacArthur studies of successful aging,” American Journal of
Public Health, vol. 84, no. 11, pp. 1796–1799, 1994.
[6] P. Scuffham, S. Chaplin, and R. Legood, “Incidence and costs
of unintentional falls in older people in the United Kingdom,”
Journal of Epidemiology and Community Health, vol. 57, no. 9,
pp. 740–744, 2003.
[7] C. Kelliher, D. Kenny, and C. O’Brien, “Trends in blind regis-
tration in the adult population of the Republic of Ireland 1996–
2003,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 367–
371, 2006.
[8] Access Economics, “The economic impact and cost of vision
loss in Australia,” Report for the Centre for Eye Research
8 Journal of Ophthalmology
Australia and the Eye Research Australia Foundation, 2004.
[9] T. Pulska, K. Pahkala, P. Laippala, and S.-L. Kivela¨, “Follow up
study of longstanding depression as predictor of mortality in
elderly people living in the community,” BritishMedical Journal,
vol. 318, no. 7181, pp. 432–433, 1999.
[10] B.W. Rovner andR. J. Casten, “Neuroticism predicts depression
and disability in age-related macular degeneration,” Journal of
the American Geriatrics Society, vol. 49, no. 8, pp. 1097–1100,
2001.
[11] B. W. Rovner and Y. Shmuely-Dulitzki, “Screening for depres-
sion in low-vision elderly,” International Journal of Geriatric
Psychiatry, vol. 12, no. 9, pp. 955–959, 1997.
[12] B. W. Rovner, P. M. Zisselman, and Y. Shmuely-Dulitzki,
“Depression and disability in older people with impaired vision:
a follow-up study,” Journal of the American Geriatrics Society,
vol. 44, no. 2, pp. 181–184, 1996.
[13] J. Tolman, R. D. Hill, J. J. Kleinschmidt, and C. H. Gregg, “Psy-
chosocial adaptation to visual impairment and its relationship
to depressive affect in older adults with age-related macular
degeneration,” Gerontologist, vol. 45, no. 6, pp. 747–753, 2005.
[14] J. C. Javitt, Z. Zhou, andR. J.Willke, “Association between vision
loss and higher medical care costs in Medicare beneficiaries.
Costs are greater for those with progressive vision loss,” Oph-
thalmology, vol. 114, no. 2, pp. 238.e1–245.e1, 2007.
[15] C. Carabellese, I. Appollonio, R. Rozzini et al., “Sensory impair-
ment and quality of life in a community elderly population,”
Journal of the American Geriatrics Society, vol. 41, no. 4, pp. 401–
407, 1993.
[16] B.Gannon, E.O’Shea, andE.Hudson, “Economic consequences
of falls and fractures among older people,” IrishMedical Journal,
vol. 101, no. 6, pp. 170–173, 2008.
[17] R. Legood, P. Scuffham, and C. Cryer, “Are we blind to injuries
in the visually impaired? A review of the literature,” Injury
Prevention, vol. 8, no. 2, pp. 155–160, 2002.
[18] C. Murray and A. Lopez, The Global Burden of Disease: A
Comprehensive Assessment of Mortality and Disability from
Diseases, Injuries and Risk Factors in 1990 and Projected to 2020,
vol. 1 of Global Burden of Disease and Injury Series, Harvard
School of Public Health, Boston, Mass, USA, 1996.
[19] M. E. Salive, J. Guralnik, R. J. Glynn, W. Christen, R. B.
Wallace, and A. M. Ostfeld, “Association of visual impairment
with mobility and physical function,” Journal of the American
Geriatrics Society, vol. 42, no. 3, pp. 287–292, 1994.
[20] A. Lafuma, A. Brezin, F. Fagnani, V. Mimaud, M. Mesbah, and
G. Berdeaux, “Nonmedical economic consequences attributable
to visual impairment: a nation-wide approach in France,”
European Journal of Health Economics, vol. 7, no. 3, pp. 158–164,
2006.
[21] B. van den Berg, W. B. F. Brouwer, and M. A. Koopmanschap,
“Economic valuation of informal care. An overview of methods
and applications,” European Journal of Health Economics, vol. 5,
no. 1, pp. 36–45, 2004.
[22] C. B. Roberts, Y. Hiratsuka, M. Yamada et al., “Economic cost
of visual impairment in Japan,” Archives of Ophthalmology, vol.
128, no. 6, pp. 766–771, 2010.
[23] R. Robinson, J. Deutsch, H. S. Jones et al., “Unrecognised and
unregistered visual impairment,” British Journal of Ophthalmol-
ogy, vol. 78, no. 10, pp. 736–740, 1994.
[24] C. Bunce, J. Evans, S. Fraser, andR.Wormald, “BD8 certification
of visually impaired people,” British Journal of Ophthalmology,
vol. 82, no. 1, pp. 72–76, 1998.
[25] R. J. Barry and P. I. Murray, “Unregistered visual impairment: is
registration a failing system?” British Journal of Ophthalmology,
vol. 89, no. 8, pp. 995–998, 2005.
[26] C. Meads and C. Hyde, “What is the cost of blindness?” British
Journal of Ophthalmology, vol. 87, no. 10, pp. 1201–1204, 2003.
[27] B. R. Shamanna, L. Dandona, andG.N. Rao, “Economic burden
of blindness in India,” Indian Journal of Ophthalmology, vol. 46,
no. 3, pp. 169–172, 1998.
[28] M. R. S. Boland, J. Vingerling, M. Groot, and L. Hakkaart-van
Roijen, “PSS9 the burden of age-related macular degeneration
in the Netherlands,” Value in Health, vol. 14, no. 7, pp. A503–
A510, 2011.
[29] H. R. Taylor, M. L. Pezzullo, S. J. Nesbitt, and J. E. Keeffe, “Costs
of interventions for visual impairment,” American Journal of
Ophthalmology, vol. 143, no. 4, pp. 561.e1–565.e1, 2007.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
